

AD _____

MIPR NUMBER: 93MM3557

TITLE: X-Ray Crystallography of Botulinum Neurotoxins

PRINCIPAL INVESTIGATOR: Martin Sax, Ph.D.

CONTRACTING ORGANIZATION: Veterans Administration Medical Center
Pittsburgh, Pennsylvania 15240

REPORT DATE: October 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 1

19960129 023

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1995		3. REPORT TYPE AND DATES COVERED Annual (1 May 93 - 30 Sep 95)
4. TITLE AND SUBTITLE X-Ray Crystallography of Botulinum Neurotoxins			5. FUNDING NUMBERS 93MM3557	
6. AUTHOR(S) Martin Sax, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Veterans Administration Medical Center Pittsburgh, Pennsylvania 15240			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Botulinum neurotoxin, type E (Bot E) was purified to evaluate the affects of purity on crystallization. It was found that purification of the product from PHLS/CAMR Proton, Salisbury, VK did not improve crystal quality significantly. Accordingly, the product was used as supplied in further crystallization experiments. Diffraction quality crystals were grown by VAMC personnel at Fort Detrick, but the crystals which were transported in sealed capillary tubes deteriorated in transportation. To overcome this problem, a safe and secure laboratory was set up in the Pittsburgh VAMC (UD) in compliance with Federal regulations to handle Bot E neurotoxin. Crystals were grown which diffracted to 3.A, and a set of intensity data was collected from it. Work is progressing with the aim of getting more mature and derivative data.				
14. SUBJECT TERMS Botulinum neurotoxins, botulinum neurotoxin type E, X ray diffraction, 3 D structure			15. NUMBER OF PAGES 6	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

Block 13. Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (*NTIS only*).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

10/24/95
Date

TABLE OF CONTENTS

Front Cover	1
SF 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body	5
Conclusion	6

BOTULINUM NEUROTOXINS - MIDTERM REPORT

INTRODUCTION:

Clostridial toxins are regarded as the most poisonous substances to mankind. There are seven serologically distinct botulinum neurotoxins, labeled A to G, secreted by *Clostridium botulinum*. These are synthesized as single chain proteins of 150kDa molecular weight but some of these serotypes are nicked by endogenous protease at about one third from the N-terminus forming a dichain molecule with one light and one heavy chain. For example, while Bot - type A is a dichain, bot type E remains as a single chain. However, Bot type E could also be nicked *in vitro* by trypsin. Dichain botulinum neurotoxins are multifold more toxic than single chain neurotoxins. While the precise nature of mechanism of action of these toxins is not known, a three step model has been proposed. In the first step neurotoxin binds to specific receptors on the presynaptic membranes and the binding site is believed to be in the C- terminal half of neurotoxin. The second step is internalization of toxin and the N terminal half of neurotoxin is involved in this. The third and final step is the intracellular lysis which takes place via the light chain. However, to understand the mechanism of action and the nature of binding sites, it is essential to have the three dimensional structure of these neurotoxins. Since the three dimensional structure of none of these toxins is known at present, we have undertaken to determine the three dimensional structure of botulinum neurotoxin, type E.

BODY:

Botulinum neurotoxin, type E (Bot-E) was obtained from PHLS/CAMR Porton Down, Salisbury, UK. The protein as obtained was pure as shown by SDS gels. Initial screening for crystallization was carried out using the hanging drop method in 24 well Linbro culture plates. Equal volumes of (2 to 3 microlitres) of protein and reservoir solutions were mixed on siliconized cover slips which were then inverted over the reservoir wells and sealed with silicone grease. Crystals were obtained over a range of 6 to 10% PEG 4000 as reservoir solution containing 0.2 M Hepes buffer in the pH range 6.8 to 7.2. These crystals were plate like crystals and preliminary x-ray diffraction experiments showed that they are in monoclinic space group P2 with cell parameters $a = 81.6$, $b = 172.87$, $c = 139.2$ Å and $\beta = 98.7^\circ$ with two molecules per asymmetric unit. X-ray diffraction data extending to 3.1 Å resolution have been collected.

Crystals were mounted in capillary tubes and then sealed before being transported to Pittsburgh from Fort Detrick. Since it was difficult to transport mounted crystals as was initially done, crystallization experiments were also moved to Pittsburgh. For this purpose a small lab was modified to be P2 biosafety level lab at the VA medical center, Pittsburgh.

A biosafety cabinet and a refrigerated micro centrifuge were purchased. The lab is now functional and is in operation. This move has increased our ability to try more experiments than in the past. We found that when 8 % PEG 6000 and 0.2 M Hepes at pH 6.8 are used we get small but chunky crystals. One data set was collected using these crystals. Further work is in progress.

Botulinum neurotoxins and tetanus neurotoxins have considerable sequence homology and may have structural similarity. The C- terminal half of the heavy chain of tetanus toxin is commercially available and if the three dimensional structure of this fragment could be determined it will serve two purposes. The structure of this fragment by itself could shed light on the binding of this fragment to specific receptors in presynaptic membranes. It could also be used as partial structural information in solving the structure of botulinum neurotoxin. In view of this, the 50 kDa C-fragment (rTTC) of the heavy chain of tetanus toxin was purchased from the Boehringer Mannheim Corporation. rTTC has been crystallized using the vapor diffusion method. Crystals are obtained with a precipitant of 14 to 18% (w/v) PEG 4000, 0.1 M imidazole, pH 6.5. Addition of salts, like $MgCl_2$, NaCl and $NaCH_3CO_2$ also encourage crystallization. Two different crystal forms grow under similar conditions depending on the initial concentration of protein and the ratio of the volume of protein to the volume of reservoir. The morphology of these two crystal forms are different and could be recognized under a microscope Plate like crystals are in space group $P2_12_12_1$ with unit cell parameters $a = 79.7$, $b = 94.0$ and $c = 71.3$ Å. Chunkier, rod shaped crystals are also in space group $P2_12_12_1$ with slightly smaller unit cell volume. The cell parameters are $a = 67.4$, $b = 79.7$ and $c = 91.1$ Å. Chunkier crystals diffract to better resolution and are more stable under irradiation by x-rays and are thus being used for structure determination.

X-ray diffraction data have been collected from native crystals to 2.6 Å resolution. Extensive heavy atom derivative search is being conducted and two suitable heavy atom derivative crystals have already been identified and data collected on them to 3.0 Å resolution. These data were used to calculate MIRAS maps. The phases were further improved by solvent flattening and the resulting map is being analyzed.

CONCLUSION:

1. More crystallization experiments are needed to get more native and derivative diffraction intensity data.

1. Though the electron density map for rTTC reveals the general structure, it is not good enough to trace the entire polypeptide chain. Currently, heavy atom derivative search is being continued to identify more derivatives to improve protein phases. With more derivatives a better map will be obtained and the chain traced.